• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Dianthus Therapeutics, Inc. - Common Stock (NQ: DNTH )

    23.80 +0.76 (+3.30%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 389,926
    Open 22.79
    Bid (Size) 9.570 (2)
    Ask (Size) 34.00 (1)
    Prev. Close 23.04
    Today's Range 22.35 - 24.21
    52wk Range 10.02 - 33.77
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics
    Via Benzinga
    Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    +107.86%
    +107.86%
    1 Month
    +6.54%
    +6.54%
    3 Month
    -9.06%
    -9.06%
    6 Month
    -6.74%
    -6.74%
    1 Year
    +106.96%
    +106.96%

    More News

    Read More
    Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts
    Via Benzinga
    A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts
    Via Benzinga
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Expert Ratings For Dianthus Therapeutics
    Via Benzinga
    Navigating 4 Analyst Ratings For Dianthus Therapeutics
    Via Benzinga
    What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
    Via Benzinga
    Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
    Via Benzinga
    Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.